Tempus AI, Inc. (NASDAQ:TEM) Receives $71.36 Average PT from Brokerages

Shares of Tempus AI, Inc. (NASDAQ:TEM) have received a consensus recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $71.3571.

Several research firms have recently weighed in on TEM. Jefferies Financial Group began coverage on Tempus AI in a research note on Monday, April 13th. They issued an “underperform” rating and a $35.00 price objective on the stock. TD Cowen upgraded Tempus AI from a “hold” rating to a “buy” rating and set a $65.00 price objective on the stock in a research note on Monday, April 13th. Mizuho began coverage on Tempus AI in a research note on Thursday, February 19th. They issued an “outperform” rating and a $100.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research note on Wednesday, March 11th. Finally, Robert W. Baird began coverage on Tempus AI in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective on the stock.

Tempus AI Trading Up 0.7%

Shares of TEM opened at $55.51 on Monday. Tempus AI has a 12-month low of $41.73 and a 12-month high of $104.32. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52. The firm has a market capitalization of $9.92 billion, a price-to-earnings ratio of -39.37 and a beta of 4.90. The stock’s 50-day moving average price is $50.86 and its 200 day moving average price is $65.22.

Insider Buying and Selling

In other news, CEO Ryan Fukushima sold 9,592 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $566,407.60. Following the sale, the chief executive officer directly owned 694,354 shares in the company, valued at approximately $41,001,603.70. This represents a 1.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the company’s stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $46.38, for a total value of $7,710,675.00. Following the completion of the sale, the chief executive officer owned 8,875,033 shares in the company, valued at approximately $411,624,030.54. This represents a 1.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 563,841 shares of company stock worth $32,258,311. Insiders own 24.26% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Victory Capital Management Inc. boosted its holdings in shares of Tempus AI by 1.5% in the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after acquiring an additional 162 shares in the last quarter. Global Retirement Partners LLC boosted its holdings in shares of Tempus AI by 29.5% in the 3rd quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock worth $59,000 after acquiring an additional 167 shares in the last quarter. US Bancorp DE boosted its holdings in shares of Tempus AI by 6.6% in the 3rd quarter. US Bancorp DE now owns 2,848 shares of the company’s stock worth $230,000 after acquiring an additional 176 shares in the last quarter. Legacy Bridge LLC boosted its holdings in shares of Tempus AI by 1.6% in the 4th quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock worth $733,000 after acquiring an additional 193 shares in the last quarter. Finally, Truist Financial Corp boosted its holdings in shares of Tempus AI by 5.8% in the 4th quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after acquiring an additional 194 shares in the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.